

## Index

### a

- abbreviated new drug applications (ANDAs) 194–196
- absolute bioavailability 239
- absorption, distribution, metabolism and excretion/elimination (ADME) 229–231, 235–237, 395
- parameters
  - active transport 229–230
  - clearance (CL) 129, 147, 212, 215, 218, 234, 235, 238, 251, 411
  - distribution 230–231
  - endocytosis and exocytosis 230
  - metabolism and excretion 231
  - passive diffusion 229
  - properties 109, 238
- accelerated insulin delivery 256
- accelerated tests 108, 109
- acceptable daily intake (ADI) 379
- acetaminophen polymorphism 37
- acetylsalicylic acid (ASA) 158
- active pharmaceutical ingredient (API)
  - 1, 22–37, 52, 55, 56, 61, 66, 76, 91–95, 98, 99, 101–105, 107–116, 128, 129, 131, 132, 134, 135, 138, 142–144, 146, 157, 171, 175, 187, 189, 191, 196, 197, 209, 282, 285, 287–288, 290–292, 296, 298–300, 302, 305, 307, 309, 369, 370
- active substance master file (ASMF) 190
- acute renal failure (ARF) 369
- adhesive dermally-applied microarray (ADAM) 252
- advance glycation end (AGE) 103
- aerosol suspensions 138
- aggregation number 77
- aldehyde impurities 99–103, 113, 114
- $\alpha$ -tocopherol (vitamin E) 112
- Amadori rearrangement 103
- Ambisome<sup>®</sup> 131
- amidation reactions 104
- 1-amino-1-deoxy-2-ketose intermediate 103
- amisulpride 10, 11
- amorphization-solid-state techniques
  - 294–298
  - crystalline hydrates 294
  - HME 296
  - milling process 294–296
  - vacuum compression moulding 296–298
- amorphization-solution based techniques
  - 291–294
  - flash/rotary evaporation 294
  - freeze drying 293–294
  - melting and quench-cooling 291, 292
  - spray drying 292–293
  - supercritical fluid processing 294
- amorphous felodipine 314
- amorphous form
  - 15, 64, 65, 82, 131, 167, 168, 178, 179, 185, 194, 197, 283–286, 290, 291, 296, 303, 310, 317, 319

- amorphous form (*contd.*)
    - amorphization-solid-state techniques
      - crystalline hydrates 294
      - HME 296
      - milling process 294–296
      - vacuum compression moulding 296–298
    - amorphization-solution based techniques
      - flash/rotary evaporation 294
      - freeze drying 293–294
      - melting and quench-cooling 291, 292
      - spray drying 292–293
      - supercritical fluid processing 294
    - API 287–288
    - co-amorphous 289–290
    - density measurements 310
    - DVS 310–312
    - limitations 285, 289
    - perfusion/solution calorimetry 307–310
    - pharmaceutical compounds 284
    - solid dispersions 285
    - stabilization of 285–287
    - thermal methods
      - differential scanning calorimetry 302–305
      - DMA 305–307
    - vibrational spectroscopy
      - MID-IR 313–316
      - NIR 318–319
      - Raman spectroscopy 316–318
      - THz 319–321
    - XRPD 299–302
  - amorphous materials, characterization
    - density measurements 310
    - dynamic vapour sorption 310–312
    - perfusion/solution calorimetry 307–310
    - thermal methods
      - differential scanning calorimetry 302–305
      - DMA 305–307
      - XRPD 299–302
  - amorphous raffinose 294
  - amorphous solid dispersion 56, 65–69, 288, 290, 296–298
  - amorphous suspensions 65
  - amphipathic nonionic surfactant 112
  - anemia 137, 412
  - anionic surfactants 77, 78
  - anterior segment 332, 336, 345, 352–354, 356, 357
    - ocular insert and implant 353–354
    - punctal plugs 352–353
    - therapy 336
  - antioxidants 71, 80, 98, 99, 111–113, 218, 379
  - anti-*salmonella typhimurium* activity 255
  - Apelblat equation 16
  - aqueous humor 332, 347, 350
  - aqueous layer 334, 407
  - area under the curve (AUC) 20, 21, 37, 142, 232–233, 241, 242, 344, 346, 349, 352
  - aromatic aldehyde impurities 100
  - Arrhenius equation 18
  - Aspirin<sup>TM</sup> 158
  - atomic force microscopy (AFM) 64, 322
  - atomization of antisolvent induced suspension (AS AIS) 37
  - Avapro<sup>TM</sup> (Irbesartan) 100
  - Avicel<sup>®</sup> 103
  - Avrami mode 27
- b**
- ball milling process 295
  - benzalkonium chloride (BAK) 347
  - benzamide 2
  - 3-(4-(benzo[d]isoxazole-3-yl)piperazin-1-yl)-2,2-dimethylpropanoic acid hydrochloride (B5HCl) 166
  - $\beta$ -cyclodextrin 139
  - $\beta$ -mannitol 33
  - betamethasone dipropionate 109, 110, 254
  - bimatoprost 340, 353, 354
  - biopharmaceutics classification system (BCS) 20, 37, 55, 56, 58, 64, 74, 76, 124, 130, 162, 196, 282, 283, 291, 350, 418

- biorelevant media 69  
 Boltzmann constant 19  
 bolus intravenous 384  
 bottom-up methods 59, 62  
 Bowman's membrane 333  
 Bragg's law 299, 300  
 bronchodilators 138  
 "browning" effect 103  
 buspirone hydrochloride 17  
 butyl hydroxyanisole (BHA) 379  
 butyl hydroxytoluene (BHT) 111, 112, 379
- C**
- calcium carbonate 2  
 Cambridge Structure Database (CSD) 1  
 carbamazepine 19, 33, 36, 37, 294  
 carboxymethylcellulose (CMC) 254  
 Casemet<sup>®</sup> 67  
 cationic surfactants 77  
 cell penetrating peptides (CPPs) 417  
 cellulose acetate phthalate (CAP) 35  
 cephalothin 314  
 cetylpyridiniumcation 93  
 cetylpyridinium chloride 93, 268  
 chelating agents 98, 99, 111, 112, 406, 410  
 chemical potential gradient 137  
 chemical stability 14, 109, 125, 142, 294, 296, 322  
 chemistry, manufacturing, and controls (CMC) 190  
 chemistry of active substances, guideline 177–180  
 chloramphenicol palmitate 20  
 9-chloro-betamethasone dipropionate 110  
 chlorocresol 112  
 chlorpromazine hydrochloride 28  
 cholecystokinin (CCK)-A receptors 104  
 chondroitin sulfate 254, 416  
 chromatographic techniques 15  
 chromatography 100  
 C-hydroxylation 237  
 circular dichroism (CD) spectroscopy 395, 402, 403  
 Claisen–Schmidt type condensation 101  
 clopidogrel 12, 17  
 co-amorphous system (CA) 289–290  
 coated microneedles 252–254, 256, 257, 260  
 co-crystal 9, 15, 164–166, 174–175, 177–181, 184, 185, 188–193, 196, 197, 283, 296  
 coformer 9, 174, 175, 190, 197  
 colon-targeted drug delivery systems 416  
 common technical document (CTD) 50, 75, 175–179, 182, 196, 197  
   drug product 177–178  
   drug substance 175–177  
 complex formulations 111, 125, 140, 251, 309  
 compound-dependent mixing ratio 65  
 compound during development 166  
 compound related factors, absorption 230  
 compressibility 11–13, 28, 33, 36, 285  
 concomitant polymorphism 6–7  
 condensation reactions 95, 99, 161, 186  
 conformational polymorphism 2–3  
 conventional supercritical anti-solvent method 36  
 conventional surfactants 128, 348  
 corneal epithelium 333, 334, 342, 344, 346, 347, 351  
 co-precipitation method 67, 68  
 cosolvent mediated solubilization 70  
 cosolvents 54, 70, 71, 74, 121, 125, 127–128, 130, 132, 135, 141, 143, 344, 357  
 Coulter counter analysis 63  
 cremophor EL 129, 144, 147, 219, 220  
 critical micellar concentration (CMC) 77, 128, 348  
 critical process parameters (CPPs) 33, 52

- critical quality attributes (CQAs) 52, 180
- croscarmellose sodium 103
- crospovidone 91, 96, 99
- cryo-milled indomethacin 291
- cryo-milling (CM) 296, 302, 303
- crystal lattice energy 298
- crystalline hydrates 294
- crystalline solid dispersions 65
- crystalline state 65, 165, 283, 299, 301, 304, 310, 313, 320
- crystallinity 23, 36, 64, 68–69, 168, 287, 293–295, 299, 308, 310, 314, 316, 318, 319, 321
- crystallization energy 308
- crystallized band 163
- crystal modification 50
- crystal morphology 10
- CsAApidSOL 348, 349
- CsA eye drop 346
- <sup>14</sup>C-spiked blood calibration standards 239
- Cyclasol<sup>®</sup> 347, 348
- cyclodextrins (CD) 128, 129, 132, 143, 147, 287, 349–351, 398
- complexations 50, 135, 146–147
- cyclooxygenase (COX) inhibitor 248
- cyclophosphamide 33
- cyclosporine A 230, 346, 418–421
- cytochrome p450 monooxygenases (CYPs) 237, 375
- cytochromes P450 (CYPs) 237, 238,
- d**
- data sources, excipients
- generally recognized as safe 376–377
- Handbook of Pharmaceutical Excipients 377
- inactive ingredient database 376
- in silico 378
- other database 377–378
- pharmacopoeias 376
- STEP database 377
- Daunosil<sup>®</sup> 131
- degradative condensation reaction 99
- degree of crystallinity 23, 64, 68, 287, 293, 314, 316, 318
- δ-mannitol 33
- dendrimers 138, 348–349, 398
- Descemet membrane 333
- design of experiments (DoE) 51, 52
- desmopressin 255, 412, 422
- developability classification system (DCS) 56
- dexamethasone (DXM) 338, 353, 358
- dexamethasone palmitate (DXP) 358
- dibasic calcium phosphate (DCPA) 32
- diethylene glycol (DEG) 369
- diethylenetriaminepentaacetic acid (DTPA) 415
- differential scanning calorimetry (DSC) 16, 29–31, 64, 69, 83, 123, 140, 171, 185, 193, 299, 301–306, 319, 402
- diffusion constant 18, 19
- dihydropyridine calcium channel blocker 314
- dimethyl sulphoxide (DMSO) 121, 127, 137, 141
- dimethylurea (DMU) 35
- dispersibility, of formulation 71
- dispersive Raman spectroscopy 317
- DissoCube technology 61, 214
- dissolution methods 69, 163
- dissolution, of solute 123, 124
- dissolution rate-limited 56, 58, 84
- dissolution test 19, 22, 69, 163, 164, 186, 196
- dissolution velocity 59, 63–65
- dissolvable microneedles 247, 254–255, 259
- dissolving or biodegradable microneedles 247
- 2,6-di-tertbutyl-4-methylphenol 113
- Doxil<sup>®</sup> 131
- Doxorubicin loaded microneedles 254
- drug-coated microneedles 247
- drug delivery system
- anterior segment
- ocular insert and implant 353–354
- punctal plugs 352–353

- cyclodextrins 349–351
  - emulsions 346–347
  - in situ gelling systems 344–346
  - multi particulate formulations 351–352
  - non-aqueous solutions 347–348
  - polymeric micelles and dendrimers 348–349
  - drug design 8, 340–342
  - drug–drug interaction (DDI) 227, 228, 236, 237, 239
  - drug nanosuspensions 58, 60, 62
  - drug–polymer matrix 287
  - drug product (DP) 52, 68, 75, 91–93, 95, 97–99, 101, 104, 105, 107, 112–116, 156, 157, 161–163, 169, 172–175, 177–178, 181, 183–187, 191–197, 247, 336, 353, 368–370, 373, 376, 379, 381, 385, 396, 421
  - drug solubilization 62, 77
  - dry binders 28
  - dry granulation 28–29
  - Dua’s membrane 333
  - drug substance (DS) 94, 98, 109–110, 156–158, 161–164, 169, 172–178, 180–187, 191–197, 265, 284, 349, 352, 359, 361, 370
  - dynamic mechanical thermal analysis (DMA) 305–307
  - dynamic vapor sorption (DVS) 10, 11, 310–313, 319
- e**
- e-beam influenced PTH stability 253
  - efflux transporter inhibitors 230
  - electromigration (EM) 263–265
  - electroosmosis (EO) 263, 265
  - Elixir Sulfanilamide* 368
  - enabling formulation techniques 50
  - enantiomerism/stereoisomerism 7–8
  - enantiotropic polymorphism 4–5, 31
  - enantiotropic thermal transitions 29
  - endophthalmitis 331
  - endothelium 333
  - enzyme inhibition 409–410
  - epinephrine bitartrate (Medihaler-Epi™) 138
  - epithelial cellmembrane 407
  - epithelium 332–334, 342, 399
  - epoxide formation 110, 237
  - erythropoietin (EPO) 255, 392
  - Eschweiler–Clarke reaction 100, 104
  - Eschweiler–Clarke type degradation reaction 104
  - estimated safe excipient dose 378–381
  - ethanol 15, 27, 36, 37, 70, 71, 127, 136, 143, 144, 359
  - ethoxylated castor oil 144
  - ethylenediaminetetraacetic acid (EDTA) 99, 111, 112, 138, 220, 253, 410
  - European Economic Area (EAA) 190
  - European Medicines Agency (EMA) 156, 174, 180–182, 188–190, 197, 256
  - European Patent Office (EPO) 157
  - European Pharmacopeia 1, 159, 163, 168, 181, 351
  - European Public Assessment Report (EPAR) 180
  - European Union (E.U.) 167, 189, 190, 338, 355
  - eutectic system 65, 287
  - evaluation uses 369
  - excipients 138–140
    - adverse effects 371
    - inactive ingredient 368
    - novel excipients 371–374
    - preclinical safety test 387
    - regulatory requirements 372–374
    - role of 368
    - selection process
      - data sources 376–378
      - estimated safe excipient dose 378–381
      - intravenous use 381–385
      - oral use 381
      - topical use 385–386
      - undesired side effects 370–371
  - exothermic process 14
  - Ex Vivo Eye Irritation Test (EVEIT) 347
  - eye, anatomy of 333

**f**

- fabricate mesoporous silica particles 83
- fasted state simulated intestinal fluid (FaSSIF) 69, 124
- 9-F-betamethasone dipropionate 110
- Federal Patent Court of Germany (BPatGE) 167
- fed state simulated intestinal fluid (FeSSIF) 124
- fenofibrate suspension (Triglide<sup>®</sup>) 61
- Fenton type reactions 97, 98
- fixed dose combination 190, 197
- flash/rotary evaporation 294
- fluence 261
- fluid bed 26, 83
  - granulation 26
- Food and Drug Administration (FDA) 9, 80, 140, 156, 174, 219, 256, 352, 372, 396
- formaldehyde-free polycarbonate 253
- formaldehyde impurities 100, 114
- formulation approaches 131, 134, 137–138, 143, 148, 262
  - aerosol suspensions 138
  - gels 138
  - microneedle drug delivery systems 137–138
- formulation development 49–85, 231, 239, 370, 375, 394–395, 398–399
  - drug candidate selection 136–137
  - penetration enhancers 137
  - thermodynamic factor 137
  - vehicle design 137
- formulation effect 136
- formulation strategies, NCE 125–131
  - CD 128
  - emulsion 130
  - pH modification 127
  - surfactants 128–129
  - suspensions 129
- Forteo<sup>®</sup> 254
- fosinopril sodium 105, 107
- Fourier transform infrared (FTIR) 298, 299, 395, 402, 404
- Fourier Transform Raman (FT-Raman) spectroscopy 316, 317
- fractional laser ablation 246, 260, 262, 263
- freeze drying 32, 33, 66, 293–294
- freeze drying-high pressure homogenization (H96 technology) 63
- freeze drying induced transitions 32–33
- functional microarray (FMA) 251
- furfuraldehyde 100

**g**

- $\gamma$ -irradiation 253
- gastrointestinal fluids 14, 37, 50, 55, 130
- gastrointestinal tract (GIT) 70, 232, 282, 399, 407
- generally recognized as safe (GRAS) 71, 130, 376–377, 411
- glioblastoma 20
- glass transition temperature ( $T_g$ ) 255, 284–286, 291, 295, 299, 304, 306, 322
- glassy matrix systems 287
- glucagon like peptides (GLPs) 398
- glucose 102, 103, 256, 334, 349, 350, 410, 414–417
- glutathione-S-transferases (GSTs) 237
- glycation 103
- glycerine 127, 138
- good manufacturing practice (GMP) guidelines 189, 406
- granulation induced transitions 25–30
  - dry granulation 28–29
  - melt granulation 29–30
  - thermodynamic and kinetic factors 27
  - wet granulation 26–28
    - fluid bed granulation 26
    - high shear granulation 26
    - metastable, solubility of 26
    - twin-screw granulation 26
- granulation time 27
- grinding induced transitions 23–25
- guanidium hydrochloride (Gdn.HCl) 403

**h**

- half-life 55, 142, 147, 214, 216,  
220, 234–236, 242, 254, 394,  
411, 417
- Handbook of Pharmaceutical Excipients  
140, 377
- heparin 255
- hepatitis B 258, 262, 401
- herpes simplex virus-2 138
- heteroatom oxygenation 237
- high molecular weight compounds,  
delivery of 251–254
- high-pressure homogenization 59–63,  
66, 129, 130, 214
- high shear granulation 26
- high-speed differential scanning  
calorimetry (HSDSC) 302, 304
- high speed stirring-high pressure  
homogenization (ARTcrystal<sup>®</sup>)  
63
- high speed ultracentrifugation  
237
- high throughput screening (HTS) 122,  
235, 282
- hollow microneedles 247, 248,  
255–258, 260
- homogeneous and amorphous solid  
dispersions 66
- hot-melt extrusion (HME) 29, 30, 66,  
67, 83, 189, 289, 296–298, 315,  
316
- human corneal cells (HCE) 347
- human in vitro metabolism 238
- human parathyroid hormone  
(1–34)-coated microneedle patch  
system 253
- hyaluronic acid microneedles 254
- hybrid approach 59, 63
- hydrochlorothiazide (HCTZ) 101
- hydrogen peroxide (HOOH) 95, 98
- hydrolytic degradation 105–107
- hydroperoxide (ROOH) 95
- hydrophilic/hydrophobic molecular  
arrangement 10
- hydrophobization 411, 412
- 2-hydroxyethoxyacetic acid (HEAA)  
369
- 2-hydroxyethyl  
12-hydroxyoctadecanoate  
(Solutol HS-15) 144
- hydroxymethylglutaryl coenzyme A  
reductase (HMG-CoA)  
inhibitors 112
- 5-hydroxymethyl-2-furfuraldehyde  
(HMF) 100, 101
- hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD)  
128, 350
- hydroxypropyl cellulose (HPC) 99
- hydroxypropylmethylcellulose (HPMC)  
345
- hydroxypropyl methylcellulose acetate  
succinate (HPMCAS) 104, 105
- hydroxypropyl methylcellulose  
phthalate (HPMCP) 104, 105
- 5-hydroxytryptamine 3 (5-HT<sub>3</sub>)  
receptor 111
- hygroscopicity 10, 23, 166, 179, 193,  
255, 285, 289
- hyper tonicity 141
- hypersensitive reactions 129

**i**

- Ibuprofen 96, 97, 316–318
- ICH Q1A (R2) stability testing 182
- ICH Q1B photostability testing  
182–183
- ICH Q1C stability testing 183
- ICH Q6A specifications 183–188
- IDD-P technology 61
- ideal gas constant 16
- ideal solubility 16
- IgG1 monoclonal antibody formulation  
115
- Ikervis<sup>®</sup> 346
- imiquimod 115
- immunostimulating agents 257
- inactive ingredient database (IID) 80,  
376, 377
- Inactive Ingredients Guide (IIG) 140
- Incivel<sup>®</sup> (telaprevir) 67
- indomethacin (triclincin  $\gamma$ -to monoclinic  
 $\alpha$ -form) 36
- infrared (IR) spectroscopy 68–69, 168
- innovative titanium microneedles 252

- in silico data sources 378, 379
  - in situ gelling formulation 344
  - insoluble drug-delivery particles (IDD-P™) technology 61
  - instilled dose 335, 340
  - insulin 215, 216, 218, 251, 255, 256, 399, 410, 412–417, 421
  - insulin delivery 256
  - intellectual property (IP) rights 156, 167, 194
  - International Council for Harmonisation (ICH) 98, 99, 108, 109, 156, 163, 164, 177, 178, 181–182, 192, 370
  - International Pharmaceutical Excipients Council of the Americas (IPEC–Americas) 372, 374
  - intestinal epithelium 238, 408, 409
  - intestinal fluid 283, 407
  - intramuscular injections 213, 214, 257, 258, 262, 405
  - intraocular pressure (IOP) 331, 339, 342, 350, 353, 354, 358
  - intraocular implants 358–360
  - intravenous (IV) 218, 219, 381, 392, 398, 422
  - intrinsic dissolution rate (IDR) 19, 171, 290
  - intrinsic solubility 14, 127, 189
  - invasive delivery 331, 332
  - INVEGA SUSTENNA® 60
  - INVEGA TRINZA® 60
  - investigational new drug (IND) 120, 121, 194
  - Investigational New Drug Application (IND) 192–193
  - in vitro models, PK 237–238
    - cell systems 237–238
    - subcellular fractions 237
  - iontophoresis 246, 247, 263–269
    - approved commercial devices 266–268
    - clinical benefits of 264–265
    - drug candidates, selection 265
    - iontophoretic device formulation 265–266
  - isomeric aldehydes 97
  - isothermal nanocalorimetry (INC) 307, 309
  - isotonic Sorensen's phosphate buffer (ISPB) 144
  - itraconazole (ITZ) 291, 292
- j**
- Johnson–MehlAvrami (JMA) 31
- k**
- Kaletra® 67
  - Kauzmann Temperature 285
  - ketose intermediate 103
- l**
- Lactose monohydrate 319, 379, 380
  - large unilamellar vesicles (LUV) 131
  - laser-assisted ablation 260–263
    - formulation aspects 262–263
    - laser-skin interaction 261
  - laser-assisted skin drug delivery 263
  - laser cutting 248
  - laser diffractometry 63, 64
  - laser micropores 261
  - latanoprostpunctal plug (L-PPDS) 353
  - lattice energy 10, 14–16, 19, 20, 23, 298
  - lidocaine 251, 252, 256, 262, 266, 267
  - light microscopy 168
  - limit of detection (LOD) 186, 306, 307, 312
  - linear regression 235
  - linear visco-elastic region (LVR) 305
  - lipid-based drug delivery systems (lipid-based DDS) 69–76
    - characterization 75
    - method of, manufacture 71–75
    - type I lipid formulations 70
    - type II lipid formulations 70
    - type III lipid formulations 70
    - type IV lipid formulations 70
  - lipid based formulations 50, 56, 81, 125, 145, 346
  - lipid formulation classification system (LFCs) 70, 71, 74–76
    - type I 71
    - type II 71



- type III 74
  - type IV 74–75
  - lipid layer 334, 346
  - lipid microparticles (LM) 414
  - Lipinski's rule of five 123, 132
  - lipophilicity 70, 130, 136, 229, 230, 246, 262, 340, 342, 407, 408
  - liposomes 58, 131, 132, 135, 140, 400, 413–415, 421
  - lithography 248
  - liver microsomes 235–237
  - lowest observed adverse effect level (LOAEL) 380
  - low molecular weight compounds, delivery of 248–252, 254–256
  - luteinizing hormone releasing hormone (LHRH) 220, 398, 399, 412
  - lyophilization 32, 33, 293, 404
- m**
- magnesium stearate 93, 105, 107
  - Maillard reaction 102, 103
  - mannitol 33, 102, 220
  - mannose 102
  - manufacturing methods 64
    - wet media milling technology 60–61
  - marketing authorization applications (MAA) 189, 194
  - mass spectroscopy 20, 100, 395
  - mass spectroscopy (MS)-based techniques 395
  - m*-cresol 112
  - mebendazole polymorphs 20, 21
  - medium chain triglycerides 144
  - medulloblastoma 20
  - mefenamic acid 17, 27
  - melt granulation 25, 29–30
  - melting and quench-cooling 291–293
  - melting enthalpy 6, 16
  - melting point, of drug 124
  - mesoporous silica particles 81–84, 242, 243
    - method of, manufacturing and characterization 83–84
    - ordered and non-ordered mesoporous silica particles 82
  - metabolic stability 109, 125, 235
  - methoxyflavone 6, 21, 22
  - methyl cellulose (MC) 129, 143
  - metoprolol 12, 283
  - micellar system 70, 76–81
    - defined 76
    - formulation development and optimization 80–81
    - mixed micelles 77
  - miconazole nitrate 113
  - microcrystalline cellulose (MCC) 32, 93–94, 99–102, 314
  - microemulsions 70, 78, 130, 144, 145, 220, 412–414
  - microfluidization method 61, 214
  - microfluidization process 61
  - micromolding 248
  - microneedle drug delivery systems 137–138
  - microneedles 247–260
    - delivery using coated microneedle
      - high molecular weight compounds, delivery of 252–254
      - low molecular weight compounds, delivery of 252
    - delivery using dissolvable microneedles
      - high molecular weight compounds, delivery of 255
      - low molecular weight compounds, delivery of 254
    - delivery using hollow microneedles
      - high molecular weight compounds, delivery of 256–257
      - low molecular weight compounds, delivery of 255–256
    - delivery using solid microneedle
      - high molecular weight compounds, delivery of 251
      - low molecular weight compounds, delivery of 248–251
  - mediated transdermal delivery 256, 259–260
  - modalities of 259
  - pre-treatment approach 251
  - types 247
  - vaccines, delivery of 257–259

- mediated transdermal delivery (*contd.*)  
 MicronJet<sup>®</sup> microneedle arrays  
 258  
 microneedle patch 257–258  
 skin insertion method 258  
 micronized suspension 129, 145–146  
 Micronjet 258  
 MicronJet600 system 256  
 MicronJet<sup>®</sup> microneedle arrays 258  
 microparticles 351, 358–360, 398, 400,  
 416  
 micropores 248, 251, 260–262  
 mid-infrared (MID-IR) spectroscopy  
 313–316  
 milling chamber 60  
 milling process 60, 61, 294, 295  
 mixed micelles 70, 77, 411  
 Mobil Crystalline Material (MCM)-41  
 82  
 modulated temperature differential  
 scanning calorimetry (MTDSC)  
 302  
 molecular dynamics (MD) 16  
 monochloroacetic acid 103, 104  
 monodisperse drug nanosuspensions  
 60  
 monohydrate formation 28  
 monosaccharides 102, 103  
 monotectic systems 65, 287  
 monotropic polymorphism 5–6  
 mucoadhesive polymeric systems 400,  
 417  
 mucous layer 334, 350–352, 399  
 multilamellar vesicles (MLV) 131  
 multicomponent compounds  
 164–166, 175, 185, 190
- n**
- naltrexone delivery 248  
 NanoCrystal<sup>®</sup> 60, 61  
 nanoemulsions 70, 130, 132, 183, 218,  
 346, 347, 358  
 NanoPure technology 61  
 nanosuspensions 58–64  
 characterization of  
 dissolution velocity 64  
 particle morphology 63, 64  
 particle size 63  
 saturation solubility 64  
 solid-state properties 64  
 surface charge 63  
 formulations 63, 219, 352  
 manufacturing methods  
 bottom-up methods 62  
 high-pressure homogenization  
 61–62  
 hybrid approach 63  
 top-down methods 59–60  
 wet media milling technology  
 60–61  
 near-infrared (NIR) spectroscopy 28,  
 313, 318–319  
 neodymium-doped yttrium aluminum  
 garnet laser (Nd:YAG) 260  
 new active substances (NAS) 188  
 new chemical entities (NCE) 1, 2, 38,  
 58, 60, 62, 120, 121, 123, 132,  
 135, 140, 147, 178, 282, 372, 395  
 new drug application (NDA) 120, 150,  
 175, 194, 268, 352, 353  
 new drug products (NDA) 50,  
 183–188  
*N*-glycoside (glycosylamine)  
 intermediate 102  
 nitroethenediamine 7  
 nitroethenediamine moiety disorder 3  
*N*-methyl fenfluramine 101, 104  
*N*-methylvarenicline 104  
*N,N*-dimethyl acetamide (DMA)  
 127  
<sup>14</sup>N nuclear quadrupole resonance  
 (NQR) 299  
 no adverse effect level (NOAEL) 54,  
 142, 380  
 non-aqueous vehicles 61  
 non-birefringence 10  
 noncovalent derivatives 191, 192  
 non-cytochrome phase I enzymes  
 237  
 non-invasive delivery 331  
 non-ionic surfactant 77, 78, 112, 114  
 non-micronized test compound 242  
 non-ordered mesoporous silica  
 materials 82

- nonporous amorphous fumed silica  
(colloidal SiO<sub>2</sub>) 81
- non-random two-liquid model (NRTL)  
16
- non-steroidal anti-inflammatory drug  
(NSAID) 93
- novel drug delivery systems (NDDS)  
412
- novel excipients 349, 371–374, 376,  
378,
- N-oxoralexifene 96
- Noyes–Whitney equation 18, 159, 213
- N-terminal amino groups 103
- N-terminal fragment 253
- nuclear magnetic resonance (NMR)  
69, 100, 113, 141, 395
- nucleophilic hydroxyl groups 104
- nucleophilic impurities 105
- nucleophilic primary amine functional  
groups 101
- O**
- octanol/water partition coefficient  
124, 283
- ocular bioavailability 334, 340, 341,  
343, 344, 347, 351
- ocular delivery 331, 337, 348, 349
- ocular formulations 331–361
  - anatomy and physiology 332–336
  - drug delivery system
    - anterior segment 352–354
    - cyclodextrins 349–351
    - emulsions 346–347
    - in situ gelling systems 344–346
    - multi particulate formulations  
351–352
    - non-aqueous solutions 347–348
    - polymeric micelles and dendrimers  
348–349
  - innovative 332
  - ophthalmic drugs
    - anti-VEGF drugs 338
    - cyclosporin A 337, 338
    - prostaglandin analogues 339
  - posterior segment delivery
    - in situ depot 357
    - intraocular implants 358–360
    - microparticles 358–360
    - prodrugs 357–358
  - routes of administration 336–337
  - topical drug administration
    - drug design 340–342
    - ocular bioavailability 340
    - patient compliance through  
packaging 354–356
    - physiological factors 343–344
    - prodrugs 342–343
- ocular insert 353–354
- ophthalmic drugs
  - anti-VEGF drugs 338
  - cyclosporinA 337, 338
  - prostaglandin analogues 339
- Ophthalmic Squeeze Dispenser (OSD)  
355
- ophthalmology 336–340, 346, 359
  - molecule development 342
- opioid antagonist naltrexone 248
- optimal formulation 255
- oral drug delivery 50, 82, 83
- oral formulations 131–134, 146, 381,  
394, 418
  - composition of 146
  - formulation development  
132–134
- oral insulin 421
- oral nanosuspensions 58
- oral protein formulations  
391–423
  - case studies
    - desmopressin 422
    - oral insulin 421
  - clinical development 418
  - colon-targeted delivery systems  
416
  - development of 406
  - mucoadhesive polymeric systems  
417
  - physicochemical properties
    - amino acids 412
    - hydrophobization 412
    - PEGylation 411–412
  - pro-drugs approach 417–418
  - proteins and peptides
    - biochemical barriers 409

- oral protein formulations (*contd.*)
    - formulation strategies for 409–411
    - physical barriers 407–409
  - ordered mesoporous silica materials 82, 84
  - organic acids 103–105
  - over-the-counter (OTC) 269, 376, 379
  - oxidation reactions, organic molecules 94
  - oxidative degradation 94–99, 103, 110–113
    - of ibuprofen 97
    - organic molecules 94
    - of raloxifene 96
  - PEG 95
  - pharmaceutical excipients 95
  - polymeric excipients 95
  - povidone 95
- p**
- P450 reactions 237
  - packing polymorphism, of caffeine 9
  - parallel artificial membrane
    - permeability assay (PAMPA) 124
  - parenteral formulations 128, 134–135, 209–222, 412
  - particle morphology 64, 129, 159
  - particles size distributions (PSD) 63, 159, 179, 184, 185, 193, 294
  - particulate formulations
    - liposomes 414–415
    - microemulsions 413–414
    - microspheres/microparticles 416
    - nanoparticles 415
    - solid lipid core particles 414
  - patents 60, 156, 167, 196, 359, 360
  - patient population 54, 247, 258, 375
  - PEGylation 248, 411–412
  - penetration enhancers 137
  - peptidase/enzyme inhibition 409–410
  - “perfusion” technique 307
  - permeability 20, 50, 55, 70, 71, 121, 123, 124, 128, 129, 136–138, 143, 209, 235, 238, 282, 283, 339, 341, 342, 400, 410, 417
  - permeation, effect of 136
  - permeation enhancers 407, 409–411, 416
  - PGF<sub>2α</sub> analogue drug 340, 342, 343
  - P-glycoprotein (P-gp) 124, 217, 230, 408
  - pharmaceutical dosage forms 19, 282, 284
  - pharmaceutical nanosuspensions 58
  - pharmaceutical salts 164
  - pharmacodynamics (PD) 53, 121, 142, 220, 239, 394, 399, 415
  - pharmacokinetics (PK) 8, 20, 21, 53, 121, 141–142, 212, 214, 220, 227–243, 252, 346, 382, 394, 395, 399, 415, 418
  - ADME, in vitro studies 235–237
  - case studies 241–243
  - in vitro models
    - cell systems 237–238
    - subcellular fractions 237
  - in vivo studies 238–241
    - absolute bioavailability 239
    - in drug development 240
    - tissue distribution 239
  - parameters
    - AUC 232–233
    - BA 233–234
    - CL 234, 235
    - half-life 234–236
    - plasma concentration time profile 231–232
    - Vd 234
  - pharmacopeias 159, 168–171, 185, 355, 376
  - phenylbutazone 15, 34
  - pH modification 127
  - phosphate buffered saline (PBS) 139, 214, 384

- photo-local lymph node assay (P-LLNA) 386
- photo-mouse ear swelling test (P-MEST) 386
- photosensitizer protoporphyrin IX (PpIX) 248
- physicochemical properties 1, 10–11, 26, 36, 55, 56, 61, 65, 66, 69, 77, 82, 83, 91, 121–123, 131, 132, 145, 157, 166, 174, 178, 184, 186, 192, 193, 218, 229, 246, 265, 283, 288, 290, 339, 340, 394–395, 402–404, 407, 411–412, 415
  - amino acids 412
  - hydrophobization 412
  - PEGylation 411–412
  - therapeutic proteins formulation 402
- physiological (body related) factors, absorption 230
- pioglitazone 16, 17, 214
- piston-gap homogenization method 61, 62
- piston-gap homogenizers 61, 62
- plasmid DNA 251
- poke and patch approach 248
- polar oily excipients 71
- poloxamer 407 345, 352
- poloxamers 80, 143, 345, 349
- polyamorphism 165, 291
- polydispersity index (PDI) 63
- polyethylene glycol (PEG) 61, 95, 96, 99, 100, 103, 113, 114, 127, 143, 144, 359, 411, 414
- poly (lactic-co-glycolic-acid) (PLGA) 215, 218–220, 398, 415, 416
- polymeric micelles 80, 338, 348–349, 351, 415
- polymeric surfactants 77, 80
- polymer matrix 69, 287, 297, 359
- polymixin B 255
- polymorphic interconversion 4
- polymorphism 1, 164, 165
  - concomitant 6–7
  - history 1–2
  - impact of, in vivo performance
    - on bioavailability, effect of 20–22
    - on dissolution rate/solubility kinetics, effect of 17–19
    - on solubility, effect of 14–17
  - impact on, drug/excipient properties 9–13
    - mechanical properties 11–13
    - physicochemical properties 10–11
  - thermodynamic-based classification of
    - enantiotropic polymorphism 4–5
    - monotropic polymorphism 5–6
  - types
    - conformational polymorphism 2–3
    - packing polymorphism 4
- polymorph concentrations 20
- polyoxyethylene-polyoxypropylene block copolymer (pluronic F68) 144
- polyoxyethylene 10 oleoyl ether (Brij 97) 144
- polyoxyl 40 hydrogenated castor oil 129
- polyoxyl 60 hydrogenated castor oil 129
- polysaccharide excipients 102
- polysorbate 20, 80, 95, 96, 99, 103, 112–115, 129, 137, 144
- polyvinyl alcohol (PVA) 103, 214
- polyvinyl pyrrolidone (PVP) 35, 95, 146, 214, 254, 255, 296, 316, 317
- poorly soluble drugs, formulation development 49–85
  - clinical development 52, 53
    - phase 1 54
    - phase 2 54
    - phase 3 55
  - enabling formulation techniques 50
  - formulation strategy 55–57
    - drug delivery strategy 56
    - thermodynamically stable strategy 56
  - mesoporous silica particles 81–84
    - defined 82
    - in vivo efficacy of 84

- poorly soluble drugs, formulation development (*contd.*)
  - method of, manufacturing and characterization 83–84
  - types of 82
- micellar system 76–80
  - characterization 81
  - defined 76
  - formulation development and optimization 80, 81
  - micelle formation configuration 77
  - mixed micelles 77
  - surfactants 77
- nanosuspensions 58–63
  - nanoformulation strategies 58
  - oral nanosuspension 58
- QbD 50–52
- QbT 50–52
- solid dispersion 64–69
  - characterization 68–69
  - classification 65
  - co-precipitation method 67–68
  - crystallinity, investigation 68–69
  - melting/fusion 66–67
  - method, of manufacturing 66
  - molecular arrangement, investigation 69
  - solvent evaporation method 67
- posterior segment delivery 356–360
  - in situ depot 357
  - intraocular implants 358–360
  - microparticles 358–360
  - prodrugs 357–358
- posterior segment therapy 337
- powder X-ray diffractometer (PXRD) 25, 29, 36, 291, 292, 298–300, 319, 321
- precipitation method 68
- preclinical formulation assessment, NCE 119–148
  - case studies
    - cyclodextrin and complexation 146–147
    - micronized suspension 145–146
    - polymer addition, in cyclodextrin-based formulations 146
    - salt approach, improving bioavailability 144–145
    - solublizers use 147
    - surfactant, use of 143, 144
    - topical gel microemulsion formulation 144
    - use of SMEDD 145
  - excipients 138–140
  - formulation and characterization 140–141
  - formulation approaches
    - aerosol suspensions 138
    - gels 138
    - microneedle drug delivery systems 137–138
  - formulation development 132–134
    - drug candidate selection 136–137
    - penetration enhancers 137
    - thermodynamic factor 137
    - vehicle design 137
  - formulation selection, PD 142
  - formulation selection, pharmacokinetics 141–142
  - formulation strategies
    - CD 128
    - cosolvents 127–128
    - emulsion 130
    - liposomes 131
    - pH modification 127
    - solid dispersions 130–131
    - surfactants 128, 129
    - suspensions 129
  - parenteral formulations 134–135
  - properties
    - permeability 124
    - solubility 123–124
    - stability 125
  - topical formulations 135–138
    - formulation effect 136
    - permeation, effect of 136
    - skin metabolism 136
    - skin, structure 136
  - toxic studies, formulation development 142–143

- use of 122
  - pre-fillable microinjection system 258
  - pregabalin 103
  - process-induced transformation (PIT)
    - 23–37
    - freeze drying induced transitions
      - 32–33
    - granulation induced transitions
      - dry granulation 28–29
      - melt granulation 29–30
      - wet granulation 26–28
    - grinding induced transitions 23–25
    - spray drying induced transitions
      - 33–35
    - super critical fluid induced transitions
      - 35–37
    - tableting induced transition 30–32
  - pro-drugs 15, 110, 162, 214, 215, 262, 265, 283, 342–343, 357–358, 422
  - propylene glycol (PG) 70, 71, 127, 138, 166, 418
  - prostaglandin analogs 339
  - protein containing microparticles 398
  - protein formulation 112, 114, 394, 396, 398–399, 402, 404–406
  - protein therapeutics 392–395, 400, 401, 416
  - pseudopolymorphism 1, 2, 7–9, 168
  - pseudopolymorphs 64, 178, 185
  - punctal plugs 332, 336, 352–354
  - purified soya phospholipid 144
  - pycnometer 310
  - pyrazinamide (PZA) 35
  - pyrazinamide metastable  $\gamma$ -form
    - 35
  - pyrrolobenzodiazepine 104
- q**
- Q6A–solid state aspects 184–186
  - quality of transdermal patches, guideline
    - 180–181
  - quality target-product profile (QTPP)
    - 52
  - quantification, of amorphicity 318
  - quantification, of crystallinity 318
  - quantitative structure activity
    - relationships (QSAR) 378
  - quantum mechanics-dependant
    - computational methods 16
- r**
- Raman spectroscopy (RS) 33, 68, 69, 185, 187, 298, 299, 313, 316–318, 322
  - ranitidine hydrochloride 3, 7, 185
  - rapid expansion of supercritical solution (RESS) 36, 62
  - rapid expansion of supercritical solutions into a liquid solvent (RESOLV) 62
  - rate constant 18, 32, 343
  - Rayleigh scattering 316
  - recombinant human ciliary
    - neurotrophic factor (rhCNTF) 112
  - recombinant human growth hormone (rhGH) 255, 399
  - recombinant human nerve growth factor (rhNGF) 112
  - recrystallization 6, 25, 26, 68, 184, 291, 303, 304, 308, 312, 319
  - refractive index 10
  - regulative systems, in E.U. vs. U.S. 197
  - regulatory aspects, for formulation
    - design 157
    - analytical techniques, of solid state pharmacopeias 169–171
    - scientific literature 168–169
    - extended timescale 158
    - impact, of solubility and dissolution rate
      - 162–163
    - formulation process modification
      - 163
      - multiple approaches 162
    - regulatory, understanding of
      - 156–157
  - single and multicomponent systems
    - 163–168
    - compound during development
      - 166
    - multicomponent compounds
      - 165–166
    - patents 167
    - pharmacopeias 168

- regulatory aspects, for formulation design (*contd.*)
    - polyamorphism 165
    - polymorphism 164–165
    - solid state constitution control
      - process 171–174
      - properties and constitution, changes 173
      - supply chain 173–174
    - solubility 158–162
      - drug development, stages of 161
      - terms for, solubility 159, 160
  - relative humidity (RH) 10, 96, 182, 300, 307, 308, 310, 311
  - residual carboxylic acid impurities 104
  - residual reactive impurities, in excipients 91–116
    - API-excipient combination 92
    - assessment, incompatibilities of API 108–109
    - drug substance, design and selection 109–110
    - formulation strategies 110
    - impact on, drug-excipient compatibility
      - aldehyde impurities 99–102
      - chemical interactions 94
      - condensation reactions 99
      - hydrolytic degradation 105–107
      - organic acids 103–105
      - oxidative degradation 94–95
      - peroxides 95–96
      - physical interactions 93–94
      - reducing sugars 102–103
      - transition metal impurities 96–99
    - impact on, drug stability 92
    - oxidative degradation, inhibition of 110–113
      - antioxidant, selection of 112–113
      - initiation inhibitors 111
      - propagation inhibitors 111–112
    - packaging and storage 115–116
    - risk assessment, for APIs
      - incompatibilities 107–108
    - risk assessment, for mitigation strategies 107–108
  - rigid amorphous fraction (RAF) 291
  - robust micellar system 80
  - roller compaction 28
  - root mean square deviation(RMSD) 4
  - rotigotine 22, 173, 180
  - route of administration (ROA) 131, 135, 140, 142, 143, 195, 213, 282, 336, 371, 372, 375, 376, 379–382, 404–405
- S**
- Safety and Toxicity of Excipients for Paediatrics (STEP) database 377
  - salt approach, improving bioavailability 144–145
  - Sandimmune® 337, 418
  - Santa Barbara Amorphous (SBA)-15 82
  - saturable elimination process 233
  - saturation solubility 59, 63, 64, 135, 283
  - scanning electron microscopy (SEM) 64, 140, 253, 257, 299
  - sc-CO<sub>2</sub> depressurization 36
  - second harmonic generation (SHG) 299
  - self emulsifying drug delivery systems (SEDDS) 70, 74, 115, 346
  - self emulsifying technologies 413
  - self-microemulsifying-drug-delivery-systems (SMEDDs) 70, 74, 130, 145, 346, 413, 414
  - self-nano emulsifying drug delivery systems (SNEDDS) 130, 147
  - semifluorinated alkanes (SFAs) 347, 348
  - semipermeable barriers 229
  - shake-flask method 15, 64
  - silanol functional group (Si-OH) 82
  - silicon dioxide (SiO<sub>2</sub>) 25, 75, 80, 81
  - simvastatin (lovastatin) 112, 291, 316
  - single and multicomponent systems 163–168
    - compound during development 166
    - multicomponent compounds 165–166



- polyamorphism 165
- polymorphism 164–165
- single-crystal-to-single crystal (SCSC)
  - polymorphism 22
- skin metabolism 136
- slugging techniques 28
- Slug Mucosal Irritation (SMI) Assay 386
- small homogenization gap 61
- small unilamellar vesicles (SUV) 131
- smart ionto system 268–269
- sodium carboxyl methyl cellulose (Na-CMC) 146
- sodium carboxymethylcellulose (SCMC) 104
- sodium hyaluronate 254, 255
  - microneedles 255
- sodium metabisulfite 99
- sodium monochloroacetate 103
- sodium starch glycolate (SSG) 101
- solid compounds 164, 174–175
  - cocrystals and solvates 174
  - polymorphism 175
  - salts and cocrystals 174–175
- solid compounds, regulatory considerations
  - chemistry of active substances, guideline 178–180
- CTD
  - drug product 177–178
  - drug substance 175–177
- EMA
  - abridged applications 188
  - ASMF 190
  - co-crystals and GMP manufacturing 189
  - MAA 189
  - NAS 188
  - pharmaceutical acceptance 190
- quality guidelines 181–188
  - ICH Q1A (R2) stability testing 182
  - ICH Q1B photostability testing 182, 183
  - ICH Q1C stability testing 183
  - ICH Q6A specifications 183–184
  - Q6A–solid state aspects 184–188
- quality of transdermal patches, guideline 180–181
- solid dispersion (SD) 50, 64–69, 130–131, 285–287
  - characterization 68–69
  - classification 65
  - coprecipitation method 67, 68
  - crystallinity, investigation 68
    - IR spectroscopy 68–69
    - Raman spectroscopy 68–69
    - XRPD 68
  - dissolution methods 69
  - melting/fusion 66, 67
  - method, of manufacturing 66
  - molecular arrangement, investigation 69
  - overview of 285–287
  - solvent evaporation method 67
  - types 286
- solid lipid core particles 412, 414
- solid lipid nanoparticles (SLN) 217, 283, 414
- solid–liquid equilibria field (SLE) 15
- solid microneedles 247, 248, 251, 254, 259, 260
- solid microstructures transdermal system (sMTS) 252
- solid polymorphism 14
- solid solutions 7, 65, 165, 175, 286, 288, 297
- solid state, analytical techniques 168–171
  - pharmacopeias 169–171
  - scientific literature 168–170
- solid state constitution control 171–174
  - process 171–174
  - properties and constitution, changes 173
  - supply chain 173–174
- solid state nuclear magnetic resonance (ss-NMR) 69, 171, 291, 299
- solid-state properties 62, 64, 123, 131, 140, 158, 163, 164, 166, 168, 173–175, 177, 179, 182, 184, 186, 187, 193, 316
- solubilisation enthalpy 14, 16

- solubility enthalpy 14  
 solubility-limited absorption 56  
 solubility, of API 287–288  
 solute carrier (SLC) 230  
 solute carrier organic anion (SLCO) 230  
 solution-enhanced dispersion by  
   supercritical fluid (SEDS) 36, 37  
 Soluvia™ 258  
 solvates 9, 15, 26, 28, 64, 160, 164–166, 168, 171–174, 177–182, 184, 185, 188–190, 192–197  
 solvation 14, 178, 179, 185  
 solvatomorphism 2  
 solvent evaporation method 67, 68,  
 solvent vapor pressures (RVp) 307  
 spherical micelle 78  
 spray-dried lactose 100, 293  
 spray drying 33–35, 37, 66–68, 289, 290, 292–294, 416  
 spray drying-high pressure  
   homogenization (H42 technology) 63  
 spray drying induced transitions 33–35  
 static calorimetry 307  
 steroids 138, 340  
 stress tests 108, 109  
 stroma 333  
 stubborn/kinetic polymorph 22  
 subcutaneous injections 212, 254, 256, 257, 263, 405  
 sulfamethoxazole polymorphism 34  
 sulfanilamide 368  
 sulfobutylether- $\beta$ -cyclodextrin (SBE $\beta$ CD) 128  
 sulfonylether- $\beta$ -cyclodextrin sodium (SBE- $\beta$ -CD) 350  
 sulfotransferases (SULTs) 237  
 sulfuric acid 100  
 summary of product characteristics (SmPC) 189  
 supercritical antisolvent (SAS) 36, 62  
 supercritical carbon dioxide 62, 294  
 supercritical CO<sub>2</sub> (scCO<sub>2</sub>) 36, 37  
 supercritical fluid 35, 36, 59, 62, 66  
 supercritical fluid induced transitions 35–37  
 supercritical fluid-mediated  
   precipitation methods 62  
 supercritical fluid processing 294  
 supercritical nitrogen (scN<sub>2</sub>) 37  
 supercritical technology 35  
 superdisintegrant 103  
 super-refined excipients 113–115  
   fatty acids 115  
   PEG 114  
   polysorbates 114–115  
 supplementary protection certificate (SPC) 167  
 surface charge 63, 218, 412, 415  
 surfactants 77, 80, 128–130, 143–144  
   classification of 79  
   molecule 76, 77, 80  
 synchrotron radiation X-ray  
   microtomography (SR- $\mu$ CT) 13  
 syringe-compatible MicronJet 600™ microneedle array 257
- t**
- tableting induced transition 30–32  
 tacrine hydrochloride 93  
 target product profile (TPP) 184, 336, 357, 369  
   excipients 369  
 tautomeric polymorphism 7  
 tautomerism 7  
 T-cell lymphoma 254  
 tear film 332–335, 346, 350, 351  
   components 335  
   structure and composition 334  
 terahertz pulsed spectroscopy (TPS) 299  
 terahertz spectroscopy (THz) 319–321  
 tetraethoxysilane (TEOS) 83  
 terahertz spectroscopic tools 291  
   (*R*)-thalidomide 8  
   (*S*)-thalidomide 8  
 theophylline anhydrate 19  
 theophylline monohydrate 28  
 therapeutic moiety 188, 190

- therapeutic proteins formulation  
 391–423  
 classification of 400  
 current market status 396–398  
 indication 392–394  
 physicochemical properties  
 402–404  
 pre-formulation/formulation  
 394–395  
 route of administrations 404–405  
 stability constraints 395–396  
 technology development 398–399
- thermal degradation 66, 291, 294
- thermodynamic-based polymorphism  
 4–6  
 classification of  
 enantiotropic polymorphism 4–5  
 monotropic polymorphism 5–6  
 thermodynamic energy, of system 57  
 thermodynamic factor 23, 137  
 thermogravimetric analysis (TGA)  
 185, 193, 299
- thermosensitive drugs 67
- 3M Hollow Microstructured  
 Transdermal System (hMTS)  
 256
- Tibotec<sup>®</sup> (etravirine) 67
- tissue distribution 239
- tolerable daily intake (TDI) 379, 380
- top-down methods 59–60, 63
- topical drug administration  
 340–356  
 drug design 340–342  
 ocular bioavailability 340  
 patient compliance through  
 packaging 354–356  
 physiological factors 343–344  
 prodrugs 342–343
- topical formulations 135–138  
 formulation effect 136  
 permeation, effect of 136  
 skin metabolism 136  
 skin, structure 136
- topical gel microemulsion formulation  
 144
- topical instillation 339, 341
- topical medication 385
- topotactic/epitactic mechanism 22
- Toxnet databases 377, 378
- transdermal iontophoretic delivery  
 264
- transdermal iontophoretic system 263,  
 265, 267–269
- transdermal medical devices 245–269  
 iontophoresis  
 approved commercial devices  
 266–268  
 clinical benefits of 264–265  
 drug candidates, selection 265  
 iontophoretic device formulation  
 265–266
- laser-assisted ablation  
 formulation aspects 262–263  
 laser-skin interaction 261
- microneedles  
 delivery using coated microneedle  
 252–254  
 delivery using dissolvable  
 microneedles 254–255  
 delivery using hollow microneedles  
 255–257  
 delivery using solid microneedle  
 248–251  
 vaccines, delivery of 257–259  
 transdermal drug delivery 249
- transition metal impurities 96–99
- transmission electron microscopy  
 (TEM) 64, 140
- trehalose 218, 255, 257, 294
- triamcinolone 3, 10, 11, 19, 262, 358
- triamcinolone acetone acetate  
 polymorphs 3
- triglycerides 71, 130, 334
- twin screw extruder 298
- twin-screw granulation 26
- U**
- Udenfriend reaction 96, 98, 99, 112
- UDP-glucuronosyltransferases (UGTs)  
 237
- “unformulated” parathyroid hormone  
 (PTH) 253
- United States Patent and Trademark  
 Office (USPTO) 157, 167

- United States Pharmacopoeia (USP)  
64, 140, 163, 185, 191, 192, 196,  
220, 376
- universal quasichemical model  
(UNIUAC) 16
- uraemia-induced platelet dysfunction  
137
- U.S. Food and Drug Administration  
(USFDA) 9, 80, 156, 219, 256,  
352, 353, 396–397, 411, 414
- naming, drug substances and drug  
products 191–192
- IND 192–193
- regulatory classification 196–197
- sources for information 190–191
- V**
- vacuum compression molding (VCM)  
296, 297
- van 't Hoff equation 16
- variant temperature–powder X-ray  
diffraction (VT-PXRD) 33
- varicella-zoster virus 258
- vascular endothelial growth factor  
(anti-VEGF drugs) 338
- vemurafenib (Zelboraf<sup>®</sup>) 68
- vibrational spectroscopy 64, 312–321
- Raman spectroscopy 316–318
- THz 319–321
- MID-IR spectroscopy 313–316
- NIR 318–319
- volatile solvents 137
- volume of distribution (Vd) 147, 212,  
234, 238
- W**
- warrant lipid digestion 70
- water content 177, 186, 190, 294
- water for injection (WFI) 384
- water-insoluble surfactants 70, 71, 74,  
77
- water selectivity 261
- water soluble surfactants 70, 71,  
74, 77
- wet and dry etching 248
- wet granulation 25–28, 52, 187, 189
- fluid bed granulation 26
- high shear granulation 26
- metastable, solubility of 27
- twin-screw granulation 26
- wet media milling-high pressure  
homogenization (smartCrystal<sup>®</sup>)  
63
- wet media milling technology  
60–61
- X**
- xenobiotic 229–231, 332, 334
- x-ray crystallography 82, 179
- X-ray powder diffraction (XRPD)  
64, 68, 69, 123, 185, 192,  
299–302
- Z**
- zeta potential 63, 147
- zolmitriptan microneedle 252
- Zosano Pharma's pipeline 253
- Zosano Pharma's solid-state 253